PHOTO
Dubai: Doctors at Rashid Hospital transplanted a small device (roughly the size of a one-dirham coin) under the skin of the chest of a 14-year old Emirati girl who was suffering from drug-resistant epilepsy seizers.
Since the successful procedure, H.A. has been able to breathe a sigh of relief as she now prepares herself for programming the device and leading a life with minimum seizures that are less severe and less frequent in nature, thus greatly improving the quality of her life and giving her a brighter future.
Dr. Abdulla Qassim, Consultant and Head of Neurosurgery at Rashid Hospital said, “The mechanism is so sophisticated that the patient does not realise there is an implant in the body. After a thorough evaluation, we concluded that the patient was the right candidate for this type of implant. We implanted the Vagal Nerve Stimulator ( VNS) device under the skin in the chest. VNS is
sometimes referred to as a "pacemaker for the brain” as it sends regular and mild impulses of electrical energy to the brain via the vagus nerve, which helps prevent epileptic seizures.”
Dr. Muhammad Al Kaylani, Consultant Neurologist and Epileptologist at Rashid Hospital said, “About one-third of people with epilepsy don't fully respond to anti-seizure drugs. This method of treatment is primarily used to treat focal or partial seizures that do not respond to seizure medications and is used for patients who are not eligible for certain types of epilepsy surgeries. It is the most advanced type of smart and self-intelligent implant and can be programmed for each patient differently. We have used the newest generation of VNS currently available in the world, making Rashid Hospital the first hospital outside Europe and North America to use this technology. The procedure helps reduce the frequency of seizures and can shorten the recovery time after a seizure. Moreover, it also reduces the emergency room visits that such patients need to undergo when they experience frequent or severe seizures. Through this treatment we are able to significantly improve the patient’s level of alertness, overall mood and quality of life.”
-Ends-
For further information, please contact:
Kamakshi Gupta and Noor Nazzal
Communications Analysts- Media Dept.
Dubai Health Authority
klgupta@dha.gov.ae nnnazzal@dha.gov.ae
+9714 2197455
About the Dubai Health Authority:
The Dubai Health Authority (DHA) was created, in June 2007, by Law 13 issued by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE, Ruler of Dubai, with an expanded vision to include strategic oversight for the complete health sector in Dubai and enhance private sector engagement.
Prior to the establishment of the DHA, the Department of Health and Medical Services, which was established in 1973, was the functioning authority that almost exclusively focused on health service delivery.
In May 2018, H.H Sheikh Mohammed, issued Law No. (6) of 2018 of the DHA. The new Law further enables the DHA to achieve its
objectives including regulating medical services in Dubai, enhancing competiveness and transparency, improving medical services and products based on international best practices and achieving the sector’s objectives according to approved strategic plans.
H.H Sheikh Mohammed also issued Decree No. 17 of 2018 establishing subsidiaries of the DHA: the Dubai Healthcare Corporation and Dubai Health Insurance Corporation to further enhance healthcare services in Dubai and enable DHA to fulfil its responsibilities and obligations.
Three new strategic sectors were also added as part of the decree; they include Strategy and Corporate Development, Health Regulation, and Shared Support Services.
In addition to overseeing the health sector for the Emirate of Dubai, the DHA also focuses on providing services through DHA healthcare facilities including Latifa, Dubai, Rashid and Hatta Hospitals, its 12 primary healthcare centers, 17 medical fitness centers and its 6 specialty centers. For more information, visit DHA’s website: www.dha.gov.ae
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
